HK1198773A1 - 來源於胎盤的貼壁細胞及其在疾病治療中的應用 - Google Patents

來源於胎盤的貼壁細胞及其在疾病治療中的應用

Info

Publication number
HK1198773A1
HK1198773A1 HK14112259.5A HK14112259A HK1198773A1 HK 1198773 A1 HK1198773 A1 HK 1198773A1 HK 14112259 A HK14112259 A HK 14112259A HK 1198773 A1 HK1198773 A1 HK 1198773A1
Authority
HK
Hong Kong
Prior art keywords
placenta
same
adherent cells
disease treatment
disease
Prior art date
Application number
HK14112259.5A
Other languages
English (en)
Inventor
Zami Aberman
Original Assignee
Pluristem Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pluristem Ltd filed Critical Pluristem Ltd
Publication of HK1198773A1 publication Critical patent/HK1198773A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/02—Coculture with; Conditioned medium produced by embryonic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
HK14112259.5A 2009-11-30 2014-12-04 來源於胎盤的貼壁細胞及其在疾病治療中的應用 HK1198773A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27298509P 2009-11-30 2009-11-30
US37145910P 2010-08-06 2010-08-06

Publications (1)

Publication Number Publication Date
HK1198773A1 true HK1198773A1 (zh) 2015-07-10

Family

ID=43901523

Family Applications (2)

Application Number Title Priority Date Filing Date
HK13101629.2A HK1174356A1 (zh) 2009-11-30 2013-02-05 來源於胎盤的貼壁細胞及其在疾病治療中的應用
HK14112259.5A HK1198773A1 (zh) 2009-11-30 2014-12-04 來源於胎盤的貼壁細胞及其在疾病治療中的應用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK13101629.2A HK1174356A1 (zh) 2009-11-30 2013-02-05 來源於胎盤的貼壁細胞及其在疾病治療中的應用

Country Status (12)

Country Link
US (3) US9175262B2 (zh)
EP (3) EP2507362A2 (zh)
CN (2) CN102639692B (zh)
AU (1) AU2010322808B9 (zh)
CA (1) CA2781649C (zh)
ES (2) ES2684599T3 (zh)
HK (2) HK1174356A1 (zh)
IL (4) IL288647B2 (zh)
MX (1) MX2012006246A (zh)
NZ (1) NZ600651A (zh)
WO (1) WO2011064669A2 (zh)
ZA (1) ZA201203748B (zh)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2200622T5 (pl) 2007-09-19 2016-08-31 Pluristem Ltd Adherentne komórki z tkanki tłuszczowej i łożyska i ich zastosowanie w terapii
US9358320B2 (en) 2008-04-25 2016-06-07 Allosource Multi-layer tissue patches
US9480549B2 (en) 2008-04-25 2016-11-01 Allosource Multi-layer tissue patches
AU2009252722A1 (en) 2008-05-27 2009-12-03 Pluristem Ltd. Methods of treating inflammatory colon diseases
EP2334783B1 (en) 2008-09-02 2016-06-22 Pluristem Ltd. Adherent cells from placenta tissue and use thereof in therapy
IL288647B2 (en) 2009-11-30 2023-12-01 Pluri Biotech Ltd Adherent cells of placental origin and their use for the treatment of heart failure
WO2011147967A1 (en) 2010-05-27 2011-12-01 Georg Duda Skeletal muscle regeneration using mesenchymal stem cells
EP2625577B1 (en) 2010-10-08 2019-06-26 Terumo BCT, Inc. Customizable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
KR20200133393A (ko) * 2010-12-17 2020-11-27 안트로제네시스 코포레이션 양막 유래 부착성 세포를 사용한, 면역-관련 질환 및 장애의 치료
EP2689008B1 (en) 2011-03-22 2017-09-27 Pluristem Ltd. Methods for treating radiation or chemical injury
CN108342350A (zh) 2011-04-15 2018-07-31 普拉里斯坦有限公司 收获细胞的方法和系统
CN102586184B (zh) * 2011-09-05 2013-10-23 博雅干细胞科技有限公司 建立胎盘间充质干细胞库的方法
EP2776057B1 (en) 2011-11-07 2020-04-15 Hina W. Chaudhry A population of cells comprising placenta-derived cells which express cdx2 for use in treatment of damaged or degenerated heart tissue by inducing cardiac regeneration
WO2013082417A1 (en) * 2011-11-30 2013-06-06 Anthrogenesis Corporation Treatment using placental stem cells
US9162011B2 (en) 2011-12-19 2015-10-20 Allosource Flowable matrix compositions and methods
EP2849501B1 (en) * 2012-05-09 2020-09-30 Samsung Electronics Co., Ltd. Method and apparatus for controlling discontinuous reception in mobile communication system
WO2014037863A1 (en) 2012-09-04 2014-03-13 Pluristem Ltd. Methods for prevention and treatment of preeclampsia
WO2014038864A1 (ko) * 2012-09-05 2014-03-13 아주대학교산학협력단 태아연골유래 세포를 이용한 면역질환의 예방 및 치료용 조성물
ME02052B (me) 2012-09-06 2015-05-20 Uredjaji i postupci za kultivaciju celija
CA2888772A1 (en) * 2012-10-19 2015-04-24 Anthrogenesis Corporation Treatment of pain using amnion derived adherent cells
EP2959909B1 (en) * 2013-02-20 2019-12-18 Samsung Life Public Welfare Foundation Composition for treating inflammatory brain diseases which includes stem cell as active ingredient
CA2899246C (en) 2013-03-13 2022-12-06 Allosource Fascia fibrous compositions and methods for their use and manufacture
WO2014141111A1 (en) * 2013-03-14 2014-09-18 Pluristem Ltd. Methods for prevention and treatment of graft-versus-host disease
EP2970882B1 (en) 2013-03-15 2018-11-28 AlloSource Cell repopulated collagen matrix for soft tissue repair and regeneration
US10039792B1 (en) * 2013-03-16 2018-08-07 Brahm Holdings, Llc Methods for the treatment of inflammation and pain using human birth tissue material composition
WO2015013862A1 (en) * 2013-07-29 2015-02-05 Qualcomm Incorporated Dynamic indication of time division (tdd) duplex uplink/downlink subframe configurations
WO2015023901A1 (en) * 2013-08-15 2015-02-19 The Regents Of The University Of California Placenta-derived multipotent stem cells
JP6633522B2 (ja) 2013-11-16 2020-01-22 テルモ ビーシーティー、インコーポレーテッド バイオリアクターにおける細胞増殖
US9795707B2 (en) 2013-12-06 2017-10-24 Allosource Methods of drying sheets of donor-provided human birth tissue
WO2015132729A1 (en) 2014-03-04 2015-09-11 Pluristem Ltd. Systems and methods for growing and harvesting cells
WO2015148704A1 (en) 2014-03-25 2015-10-01 Terumo Bct, Inc. Passive replacement of media
GB201406716D0 (en) * 2014-04-15 2014-05-28 Insphero Ag Method of preparing cells for 3D tissue culture
WO2016049421A1 (en) 2014-09-26 2016-03-31 Terumo Bct, Inc. Scheduled feed
WO2016098061A1 (en) 2014-12-18 2016-06-23 Pluristem Ltd. Methods and compositions for treating and preventing muscle wasting disorders
WO2016151476A1 (en) 2015-03-23 2016-09-29 Pluristem Ltd. Use of adherent stromal cells for enhancing hematopoiesis in a subject in need thereof
US11146376B2 (en) 2015-04-22 2021-10-12 Qualcomm Incorporated System type dependent master information block (MIB)
US10334617B2 (en) * 2015-06-16 2019-06-25 Qualcomm Incorporated System information for enhanced machine type communication
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
TW201733600A (zh) 2016-01-29 2017-10-01 帝聖工業公司 胎兒扶持組織物及使用方法
US20210205370A1 (en) 2016-02-18 2021-07-08 Pluristem Ltd. Methods and compositions for treating cancers and neoplasms
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
CA3032160C (en) 2016-08-24 2024-05-28 Arthrex, Inc. Tissue hybrid for use in repairing, reconstructing or regenerating musculoskeletal degenerative processes or injuries
US10772986B2 (en) 2017-01-26 2020-09-15 Allosource Fascia fibrous compositions and methods for their use and manufacture
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
EP3656841A1 (en) 2017-03-31 2020-05-27 Terumo BCT, Inc. Cell expansion
US20200246386A1 (en) 2017-04-24 2020-08-06 Pluristem Ltd. Methods and compositions for treating neurological disorders
US20210369786A1 (en) * 2017-10-27 2021-12-02 Alis Pharma Ltd. Fetal tissue extract, methods for producing the extract, and the use thereof
CN110090227B (zh) * 2018-04-18 2021-03-26 浙江大学 人羊膜上皮细胞在治疗移植物抗宿主病中的用途
CN108904799A (zh) * 2018-07-09 2018-11-30 夏荣木 一种抗肿瘤制剂及制备的方法
CN109652363A (zh) * 2018-11-13 2019-04-19 广东唯泰生物科技有限公司 胎盘壁蜕膜间充质干细胞分化为子宫内膜上皮细胞的方法
US11511017B2 (en) 2019-03-12 2022-11-29 Arthrex, Inc. Ligament reconstruction
US20210187037A1 (en) * 2019-04-30 2021-06-24 Alis Pharma Ltd. Fetal tissue extract, methods for producing the same, and the uses thereof
JP2022546909A (ja) * 2019-08-09 2022-11-10 アクスオロトル バイオロジックス，インコーポレイテッド ヒト羊膜細胞に由来する組成物及び関連する方法
US12043823B2 (en) 2021-03-23 2024-07-23 Terumo Bct, Inc. Cell capture and expansion
CN113322228B (zh) * 2021-04-13 2022-08-19 广东唯泰生物科技有限公司 用于治疗肿瘤的壁蜕膜间充质干细胞培养基、共培方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5902741A (en) 1986-04-18 1999-05-11 Advanced Tissue Sciences, Inc. Three-dimensional cartilage cultures
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5629186A (en) 1994-04-28 1997-05-13 Lockheed Martin Corporation Porous matrix and method of its production
US6132463A (en) 1995-05-19 2000-10-17 Etex Corporation Cell seeding of ceramic compositions
ATE227338T1 (de) 1998-03-18 2002-11-15 Massachusetts Inst Technology Vaskularisierte perfundierte anordnungen für mikrogewebe und mikroorgane
RU2249039C2 (ru) 1999-02-04 2005-03-27 Текнион Рисерч Энд Дивелопмент Фаундейшн Лтд. Способ размножения/поддержания недифференцированных гемопоэтических стволовых клеток или клеток-предшественников (варианты), способ приготовления кондиционированной среды стромальных клеток, способ трансплантации недифференцированных гемопоэтических стволовых клеток или клеток-предшественников (варианты)
CA2400485C (en) 2000-02-26 2014-04-29 Artecel Sciences, Inc. Pleuripotent stem cells generated from adipose tissue-derived stromal cells and uses thereof
US20080152629A1 (en) * 2000-12-06 2008-06-26 James Edinger Placental stem cell populations
US7504099B2 (en) 2001-12-27 2009-03-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods of inducing or enhancing connective tissue repair
US7534606B2 (en) * 2004-01-12 2009-05-19 National Health Research Institutes Placental stem cell and methods thereof
PL1835924T3 (pl) * 2004-12-23 2014-01-31 Ethicon Incorporated Leczenie choroby Parkinsona i zaburzeń związanych z tą chorobą z użyciem komórek uzyskiwanych po porodzie
AU2006330409B2 (en) * 2005-12-28 2012-07-19 Ethicon, Incorporated Treatment of peripheral vascular disease using postpartum-derived cells
EP3091071B1 (en) 2006-03-23 2019-07-03 Pluristem Ltd. Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
US20110293583A1 (en) 2006-03-23 2011-12-01 Pluristem Ltd. Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
US20110171182A1 (en) 2006-03-23 2011-07-14 Pluristem Ltd. Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
MX349225B (es) * 2007-02-12 2017-07-19 Anthrogenesis Corp Uso de celulas madre placentarias para preparar medicamentos utiles en el tratamiento de padecimientos inflamatorios.
PL2200622T5 (pl) 2007-09-19 2016-08-31 Pluristem Ltd Adherentne komórki z tkanki tłuszczowej i łożyska i ich zastosowanie w terapii
AU2009252722A1 (en) 2008-05-27 2009-12-03 Pluristem Ltd. Methods of treating inflammatory colon diseases
WO2010026574A2 (en) 2008-09-02 2010-03-11 Pluristem Ltd. Adherent cells from placenta tissue and use thereof in therapy
EP2331957B1 (en) 2008-09-02 2016-11-02 Pluristem Ltd. Methods of selection of cells for transplantation
EP2334783B1 (en) 2008-09-02 2016-06-22 Pluristem Ltd. Adherent cells from placenta tissue and use thereof in therapy
IL288647B2 (en) 2009-11-30 2023-12-01 Pluri Biotech Ltd Adherent cells of placental origin and their use for the treatment of heart failure
EP2561066B1 (en) 2010-04-23 2016-03-30 Pluristem Ltd. Adherent stromal cells derived from plancentas of multiple donors and uses thereof
WO2011147967A1 (en) 2010-05-27 2011-12-01 Georg Duda Skeletal muscle regeneration using mesenchymal stem cells
US20140017209A1 (en) 2011-03-22 2014-01-16 Pluristem Ltd. Methods for treating radiation or chemical injury
CN108342350A (zh) 2011-04-15 2018-07-31 普拉里斯坦有限公司 收获细胞的方法和系统
WO2014037863A1 (en) 2012-09-04 2014-03-13 Pluristem Ltd. Methods for prevention and treatment of preeclampsia
ME02052B (me) 2012-09-06 2015-05-20 Uredjaji i postupci za kultivaciju celija
BR112015009137A2 (pt) 2012-10-31 2017-07-04 Pluristem Ltd método para descongelamento de material biológico congelado, e, sistema para o aquecimento de um material biológico em um recipiente
WO2014128634A1 (en) 2013-02-20 2014-08-28 Pluristem Ltd. Gene and protein expression properties of adherent stromal cells cultured in 3d

Also Published As

Publication number Publication date
IL288647B1 (en) 2023-08-01
US20130004465A1 (en) 2013-01-03
AU2010322808A2 (en) 2012-07-12
CN102639692B (zh) 2015-02-04
CA2781649C (en) 2017-07-11
EP2977445B1 (en) 2018-07-25
IL220055A0 (en) 2012-07-31
ZA201203748B (en) 2013-03-27
EP2507362A2 (en) 2012-10-10
CN105112357A (zh) 2015-12-02
IL283949A (en) 2021-07-29
US20200306318A1 (en) 2020-10-01
US20160058799A1 (en) 2016-03-03
WO2011064669A2 (en) 2011-06-03
IL258037A (en) 2018-05-31
MX2012006246A (es) 2012-06-19
AU2010322808A1 (en) 2012-07-12
CA2781649A1 (en) 2011-06-03
AU2010322808B9 (en) 2014-08-07
AU2010322808B2 (en) 2014-07-17
EP2977445A2 (en) 2016-01-27
CN102639692A (zh) 2012-08-15
US9175262B2 (en) 2015-11-03
EP2977445A3 (en) 2016-03-16
IL288647A (en) 2022-02-01
WO2011064669A3 (en) 2011-12-15
ES2684599T3 (es) 2018-10-03
ES2553712T3 (es) 2015-12-11
EP2806023B1 (en) 2015-09-23
IL288647B2 (en) 2023-12-01
IL258037B (en) 2021-06-30
HK1174356A1 (zh) 2013-06-07
IL283949B (en) 2022-01-01
CN105112357B (zh) 2020-10-23
NZ600651A (en) 2014-07-25
IL220055B (en) 2018-03-29
EP2806023A2 (en) 2014-11-26
EP2806023A3 (en) 2015-03-11
US10610545B2 (en) 2020-04-07

Similar Documents

Publication Publication Date Title
HK1198773A1 (zh) 來源於胎盤的貼壁細胞及其在疾病治療中的應用
HK1222326A1 (zh) 來自胎盤組織的粘附細胞及其在治療中的用途
IL272587A (en) Adherent cells from placental tissue and their use in healing
EP2432462A4 (en) OXYGEN PROCEDURE AND COMPOSITIONS FOR THE TREATMENT OF MAMMALIAN DISEASES
GB2465291B (en) Human pluripotent stem cells and their medical use
EP2309860A4 (en) MONOCYCLIC CYANOENONES AND METHODS OF USE
ZA201100974B (en) Treatment of autoimmune and inflammatory disease
GB0921528D0 (en) Carbon and its use in blood cleansing applications
EP2401357A4 (en) HOST CELLS AND METHOD FOR THEIR USE
ZA201008392B (en) Treatment of pluripotent cells
EP2473210A4 (en) SITU-SHAPED HYDROGEL FOR TISSUE AGENTS AND BIOMEDICAL USE THEREOF
HUE041510T2 (hu) Biológiai sejtek és szövetek krioprezervációja
IL220661A0 (en) Beta-carbolines for use in the treatment of hearing loss and vertigo
GB0920258D0 (en) New medical agents and use thereof
HU0900195D0 (en) Diagnosis and treatment of gluten-induced autoimmune diseases
HUE038120T2 (hu) Transzferrin autoimmun betegségek kezelésében és/vagy megelõzésében történõ alkalmazásra
IL219444A (en) Procine for use in the treatment of blood cell infections
HK1174620A1 (zh) 吲唑基取代的二氫異噁唑並吡啶及其使用方法

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20201201